CytoMed Therapeutics Stock Quote GDTC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.755

Bid

2.48

Ask

3.00

Volume

0.00 Day's Range 0.00

1.20 52 Week Range 5.50

Market Cap

31.793M

Previous Close

2.755

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

19,540

Shares Outstanding

11,540,000

Dividend Yield

PE Ratio

-7.68

Earnings Per Share (EPS)

-0.36

Revenue

518k

Net Profit

-4.13M

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing C... CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cytomed.sg.

Headquarters

Singapore, Sgp

Founded

CytoMed Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GDTC. The last closing price for CytoMed Therapeutics was $2.76. Over the last year, CytoMed Therapeutics shares have traded in a share price range of $ 1.20 to $ 5.50.

CytoMed Therapeutics currently has 11,540,000 shares outstanding. The market capitalization of CytoMed Therapeutics is $31.79 million. CytoMed Therapeutics has a price to earnings ratio (PE ratio) of -7.68.

FeaturedActelis Networks Bags Significant Orders for Seattle and Washington D.C. New Report Shows Their Potential as Smart City Market Eyes Trillions and Infrastructure Cyber Security Gains Importance - $ASNS

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.595	-17.7611940299	3.35	3.35	2.48	38789	2.84204321	CS
4	0.485	21.3656387665	2.27	3.35	1.8302	23920	2.85476258	CS
12	1.255	83.6666666667	1.5	3.56	1.2	19540	2.57450933	CS
26	0.695	33.7378640777	2.06	3.56	1.2	42273	2.28136901	CS
52	-0.605	-18.005952381	3.36	5.5	1.2	36421	2.89473218	CS
156	-1.245	-31.125	4	9.25	1.2	105689	4.48331338	CS
260	-1.245	-31.125	4	9.25	1.2	105689	4.48331338	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PALIPalisade Bio Inc	$ 3.21 (129.29%)	19.72M
TRVITrevi Therapeutics Inc	$ 3.55 (42.57%)	1.91M
SYTASiyata Mobile Inc	$ 1.01 (35.03%)	11.27M
CDTConduit Pharmaceuticals Inc	$ 0.112 (26.84%)	11.65M
MDCXMedicus Pharma Ltd	$ 3.44 (22.86%)	548
KROSKeros Therapeutics Inc	$ 19.10 (-72.18%)	533.94k
SPGCSacks Parente Golf Inc	$ 0.5563 (-60.26%)	116.09k
PNBKPatriot National Bancorp Inc	$ 1.08 (-58.78%)	16
AVGRAvinger Inc	$ 0.455 (-44.51%)	84.16k
SFHGSamfine Creation Holdings Group Ltd	$ 1.81 (-40.66%)	276.5k
PALIPalisade Bio Inc	$ 3.21 (129.29%)	19.72M
AMPGAmplitech Group Inc	$ 2.30 (19.17%)	13.23M
CDTConduit Pharmaceuticals Inc	$ 0.112 (26.84%)	11.65M
SYTASiyata Mobile Inc	$ 1.01 (35.03%)	11.27M
LAESSEALSQ Corporation	$ 1.29 (12.17%)	8.46M